Cardiology CHA2DS2-VASc Score

University:
The University Of Western Ontario
Course:
ANAT 2200B | Systemic Anatomy of the Human Body
Academic year:

2022
Views:

466

Pages:

2
Author:

Kyuwon J.

CHA2DS2-VASc Score ● Estimation of risk stoke on systemic embolism in atrial fibrillations (AF) ● Whether or not to start oral anticoagulation (OAC) ○ Medication taken through oral ○ Inhibition of parts of coagulation cascade ○ Prevention of thrombus formation ● Vitamin K Antagonists (VKAs) ○ Warfarin ○ Inhibition of synthesis of factor 2,7,9,10 ○ Vitamin K dependent ● DOAC’s ○ Does not need routine INR ○ Faster onset than warfarin ○ Fewer drug interactions ■ Direct factor Xa inhibitors ● Apixaban, Rivaroxaban, Edoxaban ■ Direct Thrombin inhibitors ● Dabigatran Hypertensive emergencies ● BP above 180/120 ○ Acute end organ damage ■ Encephalopathy ■ Papilledema ■ AKI ○ Need IV antihypertensive treatments ■ Labetalol ■ Nitroprussides CHA2DS2-VASc scores Letter Risk Factor Points C Congestive heart failure / LV dysfunction 1 H Hypertension 1 A₂ Age ≥75 years 2 D Diabetes mellitus 1 S₂ Stroke / TIA / thromboembolism history 2 V Vascular disease (MI, PAD, aortic plaque) 1 A Age 65–74 years 1 Sc Sex category (female) 1 Interpretations ● 0 male / 1 female = low risk = No treatment is needed ● 1 male / female = Intermediate = OAC consideration by factor ● 2+ male / 3+ female = high risk = Anticoagulation Clinic ● Non-valvular AF ● Combined with HAS-BLED score ○ Assessed bleeding risk ● Guideline for DOAs applications ○ Apixaban , rivaroxaban, dabigatran Note ● Stroke risk > bleeding risk ○ Most AF patients with CHA2DS2-VASc score more than 2 ● Female alone (=1) does not mean anticoagulation

Cardiology CHA2DS2-VASc Score

Related Documents

Recommended Documents

Description

Related Documents

Almost There!

Free up your schedule!

Take 5 seconds to unlock